Robert is the President and Chief Executive Officer at Promontory Therapeutics. He is a highly respected leader with decades of global transactional and strategic leadership. Robert is the former Chairman and Chief Executive Officer of The Korea Exchange Bank, a large publicly traded company, and prior to that he ran all of Asia-Pacific for JP Morgan Chase.
Our new corporate identity is aspirational, as we continue our growth and research and development efforts because we believe that small molecule immunotherapy has arrived, and that we are leaders within this area of cancer care. Through our internal work, coupled with our ongoing collaborations with global leaders in the field, we've developed unique insight into the development of highly-differentiated small molecule immunogenic agents, including our lead therapeutic candidate, PT-112.
/PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that the Company has...